PE20090604A1 - Tratamiento de distrofia muscular de duchenne - Google Patents

Tratamiento de distrofia muscular de duchenne

Info

Publication number
PE20090604A1
PE20090604A1 PE2008001385A PE2008001385A PE20090604A1 PE 20090604 A1 PE20090604 A1 PE 20090604A1 PE 2008001385 A PE2008001385 A PE 2008001385A PE 2008001385 A PE2008001385 A PE 2008001385A PE 20090604 A1 PE20090604 A1 PE 20090604A1
Authority
PE
Peru
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
ethylsulfonil
naftalen
Prior art date
Application number
PE2008001385A
Other languages
English (en)
Spanish (es)
Inventor
Shabana Ahmed
Mark William Hooper
Karen June Etherington
Alexander Charles Weymouth-Wilson
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of PE20090604A1 publication Critical patent/PE20090604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2008001385A 2007-08-15 2008-08-14 Tratamiento de distrofia muscular de duchenne PE20090604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
PE20090604A1 true PE20090604A1 (es) 2009-05-16

Family

ID=38566447

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001385A PE20090604A1 (es) 2007-08-15 2008-08-14 Tratamiento de distrofia muscular de duchenne

Country Status (17)

Country Link
US (2) US20090048314A1 (enExample)
EP (2) EP2176246A2 (enExample)
JP (2) JP2010535830A (enExample)
KR (1) KR20100075777A (enExample)
CN (2) CN101896475A (enExample)
AR (1) AR068810A1 (enExample)
AU (2) AU2008286325A1 (enExample)
BR (2) BRPI0811315A2 (enExample)
CA (2) CA2685939A1 (enExample)
CL (1) CL2008002391A1 (enExample)
GB (1) GB0715937D0 (enExample)
IL (1) IL201908A0 (enExample)
MX (2) MX2009011967A (enExample)
PE (1) PE20090604A1 (enExample)
RU (1) RU2009141831A (enExample)
TW (1) TW200911767A (enExample)
WO (2) WO2009021748A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641880C (en) * 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
WO2017168151A1 (en) 2016-03-30 2017-10-05 Summit (Oxford) Limited Composition for the treatment of duchenne muscular dystrophy
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
EP3641741B1 (en) 2017-06-19 2024-03-20 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (enExample) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
EP0527704B1 (de) * 1991-08-08 1996-08-28 Ciba-Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
DE59509233D1 (de) * 1994-02-24 2001-06-13 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
BR9508177A (pt) * 1994-06-30 1997-09-02 Minnesota Mining & Mfg Material de impressão dental e processo para monitorar a cura do mesmo
DE69532472T2 (de) * 1994-06-30 2004-10-28 Minnesota Mining And Mfg. Co., Saint Paul Die härtung anzeigende form- und beschichtungsmasse
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
AU4562000A (en) * 1999-05-07 2000-11-21 Basf Aktiengesellschaft 4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
WO2000068210A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenone und ihre verwendung als herbizide
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
DE60018194T2 (de) * 1999-09-24 2006-01-05 Ono Pharmaceutical Co. Ltd. Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
KR100750756B1 (ko) * 2000-11-30 2007-08-20 캐논 가부시끼가이샤 발광 소자 및 표시 장치
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CA2476594C (en) * 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
MXPA05012350A (es) * 2003-05-20 2006-05-25 Transtech Pharma Inc Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma.
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
CN1882879B (zh) * 2003-09-22 2010-08-11 爱克发印艺公司 可光聚合的组合物
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555313A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
JP2008510312A (ja) * 2004-08-19 2008-04-03 エルジー・ケム・リミテッド バッファ層を含む有機発光素子およびその製作方法
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101142194B (zh) * 2005-03-14 2012-10-10 顶点制药有限责任公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
EP1960078B1 (en) * 2005-12-02 2014-03-12 Sachem, Inc. Anion-exchange displacement chromatography process
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
CA2641880C (en) * 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
IL201908A0 (en) 2010-06-16
JP2010535830A (ja) 2010-11-25
AU2008286324A1 (en) 2009-02-19
BRPI0811315A2 (pt) 2015-01-27
WO2009021748A3 (en) 2009-04-02
CN101896475A (zh) 2010-11-24
CL2008002391A1 (es) 2009-05-22
CA2685590A1 (en) 2009-02-19
MX2009011967A (es) 2009-11-19
RU2009141831A (ru) 2011-05-20
WO2009021749A3 (en) 2009-04-02
US8138351B2 (en) 2012-03-20
US20100267961A1 (en) 2010-10-21
CA2685939A1 (en) 2009-02-19
US20090048314A1 (en) 2009-02-19
AU2008286325A1 (en) 2009-02-19
JP2010535829A (ja) 2010-11-25
WO2009021748A2 (en) 2009-02-19
AR068810A1 (es) 2009-12-09
WO2009021749A8 (en) 2009-09-11
WO2009021749A2 (en) 2009-02-19
KR20100075777A (ko) 2010-07-05
GB0715937D0 (en) 2007-09-26
TW200911767A (en) 2009-03-16
BRPI0811548A2 (pt) 2014-11-18
EP2176246A2 (en) 2010-04-21
MX2009011916A (es) 2009-11-18
EP2188270A2 (en) 2010-05-26
CN101679323A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
PE20090604A1 (es) Tratamiento de distrofia muscular de duchenne
JP2010505891A5 (enExample)
FR2930137B1 (fr) Materiel de traitement d'une valve cardiaque, en particulier d'une valve mitrale.
JP2009062604A5 (enExample)
JP2009537315A5 (enExample)
EP2300433A4 (en) HIV INTEGRASE INHIBITORS FROM PYRIDOXIN
JP2010511621A5 (enExample)
EP2080777A4 (en) HARDENING ORGANIC POLYMER, METHOD OF MANUFACTURING THEREFOR AND THE POLYMERIC HARDENING COMPOSITION
NZ593004A (en) Azaazulene compounds
EP2409197A4 (en) BIOTERANEOUS BIOHARZ, METHOD FOR THE PRODUCTION THEREOF, AND PRINTING PROCESSES USING BIOTONIC BIOHARZ
JP2011073284A5 (enExample)
IT1392456B1 (it) Processo per la sintesi di di- o oligosaccaridi l-fucosilati e loro nuovi intermedi 2,3,4-tribenzil-fucosil-derivati.
WO2012031298A3 (en) Ethynylbenzene derivatives
PE20120474A1 (es) Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion
EP2336253A4 (en) AQUEOUS COATING COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR PRODUCING A COATING FILM
EP2241656A4 (en) Recycling process of valuable metals from Izo scrap
EP2241655A4 (en) Recycling process of valuable metals from Izo scrap
EP2287267A4 (en) COMPOSITION FOR A DIRECT PROOF, METHOD FOR THE PRODUCTION THEREOF AND THUS TREATED ARTICLE
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
MA47381A (fr) Procédés et micro-organismes de fabrication de 2,3-butanediol et ses dérivés à partir de composés carbonés en c1
CL2010000281A1 (es) Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion.
EP2366691A4 (en) NITROPYRIDINYLETHYLENIMINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO2015024016A3 (en) 2-piperidinyl substituted n,3-dihydroxybutanamides
JP2008177289A5 (enExample)
PE20150708A1 (es) Derivados de ariletinilo

Legal Events

Date Code Title Description
FC Refusal